This was a double-blind, phase III trial designed to show the noninferiority of a DEX-free regimen (olanzapine, palonosetron, and fosaprepitant [OPF]) compared with the DEX-containing regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results